SignaLinc® is an early-stage Biotech company created for research and development of intelligent technologies (IT) such as assay kits, biosensors and point of care (POC) devices, to improve the global diagnostic setting of infectious and non-transmissible chronic diseases.                                                       
                                                                                       
Our Patented intelligent nanotechnology uses minimally invasive liquid biopsies (Blood, plasma, serum, saliva), and recognizes highly specific molecular-biological sequences from the sample, with high sensitivity and specificity, improving early screenings, diagnostic times, treatment, and therapeutic decisions. 
                                                                                                                     
Our main purpose is to detect diseases when they can still be cured.  SignaLinc® devices represent a vast improvement over the traditional molecular diagnostic tools. It’s a nanotechnology, point of care system that achieves the perfect balance between time and specificity, detecting the diseases biomarkers in less than 30 minutes, Providing an accurate diagnostic for timely decisions for prevention, prognosis and personalized therapeutics.  

Detecting Diseases It they can still be cured.

SignaLinc® LLC. Intelligent Molecular Research

Org chart

Teams

Offices

Similar companies